Oncology

Colon carcinoma and acute diverticulitis have similar computed tomography imaging features that can make differential diagnosis difficult for radiologists, but a novel artificial intelligence assistance model was shown to help diagnostic accuracy.

The findings suggest that both high-risk patients and high-risk regions should be considered in clinical and policy strategies to facilitate timely breast cancer care.

Pretreatment interstitial lung abnormalities were associated with worse overall and cause-specific survival in Japanese patients receiving chemoradiotherapy followed by adjuvant durvalumab for locally advanced non–small-cell lung cancer.

A preplanned analysis of the PACIFIC-R confirms findings from the pivotal PACIFIC trial of durvalumab as consolidation therapy in unresectable NSCLC after chemoradiotherapy.

The findings on tumor mutational burden (TMB) may fill a gap in biomarkers for patients who have non–small cell lung cancer (NSCLC).

A recent study found potential significance in PD-L1 analysis results for predicting immune treatment response in patients with advanced endometrial carcinoma.

Coverage from the New York City presentation of the Institute for Value-Based Medicine, co-chaired by Emeline Aviki, MD, MBA, of Memorial Sloan Kettering Cancer Center (MSKCC), and Robert Daly, MD, MBA, medical oncologist and lung cancer specialist at MSKCC.

Featured coverage from the 70th Annual Roy A. Bowers Pharmaceutical Conference, held September 19, 2022. The theme for the 2022 conference was Innovation Through Crisis: Redefining Health Care Delivery.

Implications of Telehealth Use on the Future of Oncology Care

The concluding keynote address at the Academy of Managed Care Pharmacy Nexus 2022 meeting discussed new and emerging oncology drugs in the pipeline and their potential impact on the treatment landscape as it pertains to managed care providers.

The sessions align with the yearlong theme selected by this year’s ACCC president, David R. Penberthy, MD, MBA, when he took the helm in March: “Leveraging Technology to Transform Cancer Care Delivery and the Patient Experience.”

Despite the potential incentives for medical oncologists to reduce radiation therapy utilization under the Oncology Care Model, we find no evidence that such reduction occurred.

The targeted therapy, to be sold by Taiho Oncology as Lytgobi, had previously received breakthrough status in 2021 and was accepted for priority review in March.

HHS declared a public health emergency in Puerto Rico due to Hurricane Fiona; nearly 1 in 10 Americans suffered from depression in 2020, and a task force recommended doctors screen all adults aged younger than 65 for anxiety; advances in cancer research have led to reduced cancer death rates.

The rise of telehealth during COVID-19, its limitations, and its uncertain future.

A team of investigators from across the United States investigated a potential connection between patients’ health insurance literacy and their reported financial hardship.

Ravi B. Parikh, MD, MPP, assistant professor, Department of Medical Ethics and Health Policy and Medicine, Perelman School of Medicine, University of Pennsylvania, presented long-term results from an experiment with an algorithm designed to prompt oncologists to have serious illness conversations.

Benjamin Robbins, MD, MBA, venture partner at GV, explains how the venture capital firm decides to invest in health care companies.

A survey was conducted to determine opportunities to aid primary care providers and patients in the difficult journey of an oncology patient.

Frist Cressey Ventures' main mission is to learn how it can partner with entrepreneurs to improve health care, said Chris Booker, partner with Frist Cressey Ventures.

At a panel for the National Health Alliance, 3 experts talked about incorporating patient needs and requests in cancer care.

Although the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.